Answer
The most commonly reported adverse reactions to maribavir (Livtencity) in the Phase 3 study were taste disturbance (46%), nausea (21%), diarrhoea (19%), vomiting (14%) and fatigue (12%).
Sources for this answer
- LIVTENCITY 200 mg film coated tabletsTakeda UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 5Document updated
Sources checked